The correlations between dynamic contrast enhanced magnetic resonance imaging and immunohistochemical data in head and neck squamous cell carcinomas.
Head and neck region
dynamic contrast enhancement
immunohistochemical data
magnetic resonance imaging
squamous cell carcinoma
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
19
03
2022
accepted:
21
09
2022
entrez:
22
3
2023
pubmed:
23
3
2023
medline:
24
3
2023
Statut:
ppublish
Résumé
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) can in vivo characterize tumor microvascular environment. The aim of the present study was to reveal the DCE-MRI findings and to determine the correlation between these findings and immunohistochemical data in head and neck squamous cell carcinoma (HNSCC). Thirty-three patients diagnosed with primary HNSCC were evaluated retrospectively. DCE-MRI was conducted in all cases. CD34, CD105, and ki-67 expressions were analyzed with immunohistochemistry in tissue sections to determine micro-vessel density and proliferative activity. The DCE-MRI is a successful technique in distinguishing tumor tissue from normal tissue. It was determined that Ve, Ktrans, and ki-67 values were significantly higher in high-stage tumors and there were positive correlations between the Ktrans value (by standard ROI) and CD34 MVDmax and CD34 MVDmean values. No statistically significant correlation was determined between other parameters in DCE-MRI and immunohistochemical data, and T stage. DCE-MRI could successfully differentiate tumor tissue in HNSCC. Furthermore, it was observed that DCE-MRI had the potential to reveal certain immunohistochemical information in vivo.
Sections du résumé
BACKGROUND
BACKGROUND
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) can in vivo characterize tumor microvascular environment. The aim of the present study was to reveal the DCE-MRI findings and to determine the correlation between these findings and immunohistochemical data in head and neck squamous cell carcinoma (HNSCC).
METHODS
METHODS
Thirty-three patients diagnosed with primary HNSCC were evaluated retrospectively. DCE-MRI was conducted in all cases. CD34, CD105, and ki-67 expressions were analyzed with immunohistochemistry in tissue sections to determine micro-vessel density and proliferative activity.
RESULTS
RESULTS
The DCE-MRI is a successful technique in distinguishing tumor tissue from normal tissue. It was determined that Ve, Ktrans, and ki-67 values were significantly higher in high-stage tumors and there were positive correlations between the Ktrans value (by standard ROI) and CD34 MVDmax and CD34 MVDmean values. No statistically significant correlation was determined between other parameters in DCE-MRI and immunohistochemical data, and T stage.
DISCUSSION
CONCLUSIONS
DCE-MRI could successfully differentiate tumor tissue in HNSCC. Furthermore, it was observed that DCE-MRI had the potential to reveal certain immunohistochemical information in vivo.
Identifiants
pubmed: 36945990
doi: 10.55730/1300-0144.5543
pmc: PMC10390131
doi:
Substances chimiques
Ki-67 Antigen
0
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1950-1957Références
J Magn Reson Imaging. 2019 Jun;49(7):e101-e121
pubmed: 30451345
Acta Radiol. 2019 Aug;60(8):962-968
pubmed: 30458629
Eur J Radiol. 2015 Sep;84(9):1805-9
pubmed: 26066470
Eur Radiol. 2010 Oct;20(10):2358-66
pubmed: 20443116
Radiol Med. 2011 Apr;116(3):366-74
pubmed: 21298356
Eur Arch Otorhinolaryngol. 2015 Jul;272(7):1569-76
pubmed: 24890978
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1176-83
pubmed: 21546171
J Magn Reson Imaging. 2002 Oct;16(4):407-22
pubmed: 12353256
Eur Arch Otorhinolaryngol. 2003 Oct;260(9):502-8
pubmed: 12736744
Br J Cancer. 2007 Jan 29;96(2):189-95
pubmed: 17211479
Magn Reson Med. 2006 Nov;56(5):993-1000
pubmed: 17036301
Eur Radiol. 2013 Jun;23(6):1495-502
pubmed: 23377545
Oncotarget. 2017 May 10;8(35):59492-59499
pubmed: 28938652
AJNR Am J Neuroradiol. 2016 Apr;37(4):588-95
pubmed: 26427839
Turk Arch Otorhinolaryngol. 2015 Jun;53(2):47-50
pubmed: 29391979
Curr Med Imaging Rev. 2009 May 1;3(2):91-107
pubmed: 19829742
Eur J Radiol. 2019 Mar;112:112-120
pubmed: 30777199
Transl Oncol. 2017 Feb;10(1):17-21
pubmed: 27888709
Eur Arch Otorhinolaryngol. 2018 Jul;275(7):1845-1851
pubmed: 29748768
Eur Arch Otorhinolaryngol. 2004 Aug;261(7):376-80
pubmed: 14605812
J Clin Invest. 2012 Jun;122(6):1951-7
pubmed: 22833868
Curr Med Imaging Rev. 2018 Jun;14(3):416-421
pubmed: 29910699
Oral Oncol. 2014 Oct;50(10):963-70
pubmed: 25116700